Editorial Board

Dr. Jeanetta du Plessis, earned her Ph.D. in Pharmaceutics and started her career as Senior Assistant in the Department of Pharmaceutics in 1984. At present, she is a professor of Pharmaceutics and the Director of the Centre of Excellence for Pharmaceutical Sciences (Pharmacen). She has gained International experience as a visiting scientist at the University of Michigan, USA, and as a visiting research fellow at the University of Cardiff, UK. She is an active scientist with a strong research-, innovation- and postgraduate student output Trajectory. Her Research mainly focuses on the optimization of topical and transdermal drug delivery. She is an author/co-author of numerous patents, chapters in books, and more than 81 International peer-reviewed research papers and has participated extensively at national and international conferences. She has been a National Research Foundation-rated scientist since 1995 and an established researcher and according to Google scholar, her total number of citations is 1355, her H-index is 20 and i10-index is 33. Her research findings were published in high impact pharmaceutical journals with impact factors of well over 3.
She is an expert in transdermal and topical drug delivery research and her novelty of research has reflected by international patents on her research. She has contributed to science, both in national and international, and reviewed numerous scientific manuscripts on transdermal delivery research for international peer reviewed journals.
Presently she is the member of the Department of Science and Technology, Nanotechnology, Health and Safety Executive advisory committee, the Controlled Release Society, the South African Pharmaceutical Society, the South African Academy of Pharmaceutical Sciences, the South African Society of Cosmetic Chemists, the South African Academy of Science and Arts, the Academy of Science of South Africa (ASSAf) and the Organization for Women in Science for the Developing World (OWSD).

Drug delivery
Transdermal drug delivery
Topical drug delivery
Cosmeceuticals

Professor Peter Seville graduated with a Bachelor of Pharmacy degree from the Welsh School of Pharmacy, Cardiff, following which he undertook his pre-registration pharmacist placement at St Peter’s Hospital, Surrey. He then spent some time as a basic grade pharmacist at the Royal Free Hospital, London, before returning to Cardiff University to commence a PhD investigating the development of solution pressurised metered dose inhaler systems. Following a brief spell as a community pharmacy manager in Caerphilly, he returned once more to Cardiff to a postdoctoral research position investigating pulmonary delivery of non-viral gene therapies.

Peter joined Aston University, Birmingham as a Lecturer, subsequently Senior Lecturer, in Pharmaceutics in 2002. He led the Inhalation Technology Research Team, published several original research papers and has a patent in the area of pulmonary drug delivery. Peter also served as a member of the Academy of Pharmaceutical Sciences Inhalation Focus Group steering committee, and co-organised a number of symposia and conferences in the area of inhalation science.

Following a few years pursuing personal interests, Peter returned to academia, joining the University of Birmingham as Deputy Head of Pharmacy, developing a new integrated MPharm degree. Recently, Peter has been appointed Professor of Pharmaceutical Sciences and Head of the School of Pharmacy and Biomedical Sciences at the University of Central Lancashire.

Peter has a long history of research in the development of inhalable formulations, and in particular expertise in the use of spray-drying technology to generate powders with enhanced aerosolisation properties.

Prof. Peter Seville's research interests are in the field of drug delivery, focusing on delivering drugs to the lung. He also has particular interests in healthcare law and ethics, veterinary pharmacy and healthcare education.

Dr Ka-Wai Wan is a pharmacist by training and graduated from The School of Pharmacy (University of London). She was trained as a hospital pharmacist before completing her PhD in targeted polymeric drug delivery systems at the Welsh School of Pharmacy (Cardiff). Ka-Wai is currently working as a Principal Lecturer in Pharmaceutics and a Course Leader for the MSc Industrial Pharmaceutics course at the School of Pharmacy and Biomedical Sciences at the University of Central Lancashire (UCLan, Preston). Her research interests lie in the field of advanced drug delivery systems (polymers, liposomes and colloidal systems) for targeted therapy and delivery of macromolecules such as nucleotides and proteins. She is particularly interested in the applications and biological fate (intracellular trafficking and toxicological effects) of these nanostructured delivery systems for the treatment of diseases. Current research projects involve targeting to the tumor endothelium using integrin-targeted nanoparticles as a means of anti-angiogenic or vascular targeting for the treatment of cancer and the use of nanoparticulate drug delivery systems for enhanced localization and delivery of anti-infectives through the skin.

Dr Ka-Wai Wan principal research interests lie in the field of advanced drug delivery systems (polymers,liposomes and colloidal systems) for targeted therapy and macromolecules delivery. She is particularly interested in polymer therapeutics as polymers have the advantages of being versatile and multifunctional. Past research experience has focused on nanomedicine with the use of polymeric materials as vascular targeting agents via the v3 integrin system, for the drug delivery of conventional drugs and macromolecules such as DNA and proteins. Studies on their uptake mechanism and intracellular fate were also carried out. Current research projects also involve the use of nanoparticulate systems for enhanced localization and delivery of anti-infectives through the skin as well as the development of polymer and lipid-based nanoparticulate drug delivery systems for the treatment of solid tumors

Dr. Hussein Osman Ammar is the First Class Gold Medalist in Sciences and Arts and the recipient of the 2010 Appreciation State Prize in the realm of Advanced Technological Sciences. Professor Ammar is currently the Chairman, Pharmaceutical Technology Department, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt; formerly, Dean of the Pharmacy Division, National Research Centre, Cairo, Egypt. He has 114 research papers published in international scientific journals. These research papers cover most of the areas related to pharmaceutics, biopharmaceutics and pharmacokinetics. Design of new drug delivery systems is not beyond the scope of his interest.

Nanotechnology
Drug delivery systems
Pharmacokinetics and Clinical Pharmacy

Dr Larhrib was educated at the University of Sciences and Technology, Lille I and the faculty of Pharmacy, Lille II, France where he obtained an MSc Biochem, DU Pharm, DESS Pharm. Tech. and a certificate in Pharm. Chemistry. He moved to the UK to do a PhD in Pharmaceutical technology at Liverpool John Moores University, using high speed compaction simulator to fundamentally study the mechanism of compaction of pharmaceutical powders under the supervision of Dr. James Wells and Prof. Mike Rubinstein (1994-1998). Following his PhD, Dr Larhrib worked for 4 years (1998-2002) as Senior Research Fellow in Pharmaceutics at the Department of Pharmacy, King’s College London. He worked at Liverpool John Moores University as a Senior lecturer in Pharmaceutics for 6 years (2002-2007) before joining the industry; Solid Solution Limited, Liverpool (2007-2010). He was involved in cosmetic products development and manufacture. He moved to Medway school of Pharmacy before joining the University of Huddersfield as a Senior lecturer in Pharmaceutics in July 2011. Dr. Larhrib is a regular reviewer for many international Pharmaceutical journals and member of editorial board of journal of International Research in Medical and Pharmaceutical Sciences and British Journal of Pharmaceutical Research.

Mechanism of compaction of Pharmaceutical powders
Particle Engineering to enhance therapeutic value of medicines
Nanomedicine design, formulation and delivery
Transdermal drug delivery
Pulmonary drug delivery
Cosmetics design, formulation and manufacture.

Dr. Kehinde Ross is a senior Lecturer in Biochemistry and Cell Biology at Liverpool John Moores University, Liverpool, United Kingdom. Prior to that he completed postdoctoral research in Dermatological Sciences at Newcastle University under the guidance of Professor Nick Reynolds. For his PhD at the University of Sheffield, he studied cytokine signaling proteins associated with inflammatory diseases, under the supervision of Dr. François Guesdon and Professor Steve Dower, including a year at Glaxo SmithKline under the supervision of Dr. Filippo Volpe.
He is the member of  Biochemical Society, the British Society for Investigative Dermatology, the Physiological Society, the British Hail and Nail Society and an affiliate member of the Royal Society of Chemistry.

Dr. Kehinde Ross current research focuses on the role of microRNAs and associated pathways in skin disorders such as psoriasis, eczema, impaired wound healing and alopecia. The abilities of small molecules to modulate such pathways are being investigated. He also has an interdisciplinary collaboration on the development of lipid and polymer nanocarriers for miRNA-directed therapy for inflammatory diseases.

Dr Farideh Javid is a Senior Lecturer in Pharmacology at the Department of Pharmacy, University of Huddersfield, UK. She developed the Pharmacology modules for the MPharm course at the University of Huddersfield for years 1, 2 and 3 and her on-going research programmes focus on identifying and investigating the mechanism of actions of novel drugs in cancer Pharmacology. Her ultimate aim is to develop novel drugs for cancer patients. She holds several patents as a result of her collaboration with industry.

Cancer Pharmacology
Gastrointestinal motility
Identifying novel therapeutics with anti-cancer/anti-inflammatory activity Pharmacology of cannabinoids and Herbal Medicine.

Dr. Craig Russell has always had a strong interest in science and in particular human biology, health and disease and the associated interventions. His undergraduate degree in Human Biology mapped onto this interest and included molecular and cellular biology, biochemistry and physiology modules among others, which would carry relevance in the physiology and pharmacology setting he progressed into. He further developed his knowledge and bolstered his interest in these fields during his PhD. During this period, formulation of oral liquid antihypertensives formed the initial stages of his project; here an understanding of the chemical and physical properties of drug molecules as well as drug action on a molecular level in a physiological setting was essential. In vitro and In vivo characterization of developed formulations utilising cell and rodent based models paved the way for subsequent genomic investigations into intestinal transporter expression profiling using microarray technology and bioinformatics. Cell culture played a key role during a spin off project which he has been developing in parallel with the main path of research which has seen the isolation and characterization of a novel primary cell line aimed at delineation of gustatory sensation.

Dr. Craig Russell intend to further research on oral liquid formulation targeting the paediatric patient segment by taking the research in a direction of his own to further advance in vitro and in vivo drug absorption modelling. The aim is to benefit the drug development pipeline through an innovative application of novel approaches to permeability assays including genomic and metabolomic approaches not currently exploited while at the same time seeking to enhance and advance the technologies and methodologies used in all of these areas on a day to day basis.

Chandra P. Sharma is the Acting Head of Biomedical Technology Wing and Associate Dean - PhD Programme, Sree Chitra Tirunal Institute for Medical Science & Technology, Kerala, India, and has been the Head of the Biosurface Technology Division since 1980. His areas of expertise include: biomaterials science and engineering; polymeric and metallic micro/nano particles based delivery systems; and surface modification and tissue/blood compatibility of materials. Dr. Sharma has published over 325 research papers with over 6500 citations (Scopus) and has processed over 40 patents including in Canada, European Union, Japan and USA. He has served as guest editor and reviewer of several international journals and has edited books with Dr. Michael Szycher on Blood Compatible Materials and Devices, and on Biointegration of medical implant materials: Science and design, with Woodhead Publishing. His laboratory has completed leading research in the field.

Surface modification and blood compatibility
Drug delivery
Oral insulin delivery systems

Dr. Vivek Agrahari obtained his Ph.D. in Pharmaceutical Sciences at the University of Missouri-Kansas City (UMKC), Kansas City, MO, USA. Before joining the Ph.D. program at UMKC, he did his Master of Pharmacy studies with specialization in Medicinal & Pharmaceutical Chemistry from Shri G. S. Institute of Tech. and Science, Indore, India. He worked on NIH funded research projects aimed at developing bio-responsive formulation development for the prevention and treatment of HIV/AIDS infections. His research was focused on nanoformulation development, preclinical safety evaluation, toxicology, tissue drug distribution, and HIV efficacy of bio-responsive nanomicrobicides. Dr. Agrahari has published several peer reviewed research papers, received several research awards and got opportunities to present his work at various international conferences. He is a member of numerous professional organizations. He is serving as a reviewer and also a part of the editorial board of several scientific journals.

Nanoformulations
Novel Delivery Systems
Bioanalytical Assays
Stability Evaluation
Biodistribution and Pharmacokinetics Assays
Polymer Chemistry
Targeted Drug Delivery

Dr. Drenberg is currently a Research Assistant Professor at The Ohio State University in the College of Pharmacy, Division of Pharmaceutics and Pharmaceutical Chemistry. She studied biomedical sciences at the University of South Florida in her hometown of Tampa, FL and proceeded to earn her Ph.D. from the College of Medicine in Medical Sciences. She is passionate about identifying new treatment strategies for orphan diseases, like pediatric acute myeloid leukemia.

Dr. Drenberg’s primary research goals are to integrate genomic and transcriptomic data that define specific subtypes of pediatric acute myeloid leukemia (AML) with cutting-edge high-throughput screening techniques in order to identify novel therapeutic strategies to evaluate in preclinical models, translate the findings to clinical trials, and ultimately improve long-term outcome of childhood AML. The current focus of her laboratory is on the validation of leads identified in a high-throughput drug screen, with an interest in compounds demonstrating broad activity across subtypes and compounds with subtype selectivity. Her research incorporates clinical pharmacology principles (pharmacokinetics, pharmacodynamics, drug metabolism, drug transport, drug-drug interactions) during all aspects of drug development.

Dr. Rajkumar J. Sevak has been conducting research on mental health, and providing clinical services as a pharmacist in academic settings. Currently, he is an adjunct faculty member at Auburn University School of Pharmacy. Previously, he received PhD in pharmacology from University of Texas Health Science Center and served as a faculty member at University of California, Los Angeles. He has published several articles in reputed journals and presented at numerous research conferences across the nation. He has been Principal Investigator and Co-Investigator on large-scale research grants (totaling over $11 million) that he obtained from NIH and private organizations. He also served as manuscript reviewer for many journals. In recognition of my academic accomplishments, he received awards from reputed organizations such as American College of Neuropsychopharmacology and College on Problems of Drug Dependence.

Pharmacology
Applied Pharmacy Practice
Community pharmacy
Pharmaceutical Care Services
Ambulatory Care
Pharmacodynamics
Drug Development
Adverse Drug Reactions
Clinical Research
Actions of Drugs Mental Health
Substance Abuse
Psychiatry and Neurology
Clinical Trials
Pharmacokinetics

Dr. George Matthaiolampakis has a Bachelor’s degree on Chemical Engineering from the National Technical University of Athens and received his Ph.D. from the School of Pharmacy at the University of Patras. Dr. Matthaiolampakis worked as a post-doctoral associate for two years at the NCI Center of Cancer Nanotechnology, Department of Pharmaceutical Sciences, School of Pharmacy, at Northeastern University. Prior to Northeastern University, the he worked for four years as a post-doctoral associate at the Division of Cancer Prevention, School of Medicine, at Stony Brook University. Dr. Matthaiolampakis is currently working as an Assistant Professor (tenure track) of Pharmaceutics at the Department of Basic Pharmaceutical Sciences, School of Pharmacy, at the University of Louisiana at Monroe. His lab is interested in using polymer-based nanomedicine to promote scientific knowledge in cancer treatment by integrating nanotechnology, imaging science, gene therapy and cancer biology. Based on pharmaceutical sciences, his research focus expands to mechanistic studies of compounds and nucleic acids, for gene regulation and treatment on a panel of diseases. His immediate research projects involve: 1) The use of siRNAs or miRNAs to regulate gene expression of key anti-apoptotic genes to inhibit chemoresistance and metastasis in lung and pancreatic cancer. 2) Utilization of nanotechnology for targeted delivery 3) Formulation design for crossing the Blood Brain Barrier and treatment of glioblastoma multiform for delivery of therapeutic compounds

Drug Delivery
Nanotechnology
Nucleic Acid delivery and therapy
Cancer treatment

Qian Zhong is currently a postdoctoral fellow at the Department of Pharmaceutics of Virginia Commonwealth University, Richmond, Virginia, USA and will start postdoctoral fellow position in Oct. 2016 at Stanford University. He received Ph.D degree of Material Science from the Department of Chemical Engineering and Material Science at Wayne State University, Detroit, Michigan, USA at 2016. His research interests include nanomedicine for cancer chemotherapy and immunotherapy, dendrimer chemistry, polymer synthesis, pulmonary drug delivery, and nasal/oral inhalation formulation technology. He is also the member of a few professional societies including American Institute of Chemical Engineers, American Association of Pharmaceutical Science, and Respiratory Drug Delivery. He has published 34 peer-reviewed research articles and conference paper. I have had 21 oral/poster presentations in national and international conferences since 2012.

Drug and gene delivery
Pulmonary drug delivery
Polymer synthesis and polymeric composites

Dr. Wenchao Sun is a senior research scientist in the Biomaterials and Advanced Drug Delivery (BioADD) Laboratory at Stanford University, California, USA. A biochemist by training, Dr. Sun has strong research experience in biologics delivery systems (protein and gene delivery) and bioanalytical techniques. He received his undergraduate degree in Biological Science from Tsinghua University, Beijing, China. He went on to pursue his PhD in Dr. Pamela B. Davis lab at Case Western Reserve University, Ohio, USA. While learning about Cystic Fibrosis in Dr. Davis lab, he became interested in non-viral gene delivery as a novel therapy for this genetic disease. He studied the interaction of polymer based DNA nanoparticles with cells and acquired experience in bioconjugation. His work was twice selected for oral presentation at the annual meetings of American Society of Gene & Cell Therapy. Dr. Sun then joined the BioADD lab at Stanford University for his postdoctoral training where he expanded his interest in drug delivery to include therapeutic proteins and small molecules. He soon became an expert in transdermal protein delivery using microneedles. He also delved into the mechanistic study of a small molecule drug for Alzheimer’s disease. He is now in charge of the Bioanalytical Division of the lab where he uses LCMS to conduct bioanalysis and metabolite ID of small molecule drugs. Dr. Sun has continuously published first author and co-author papers in high impact journals. He has served as reviewers for more than a dozen influential peer-reviewed journals in the field of biomatierals and drug delivery.

Controlled release of biologics using nano- and micro-particles
Transdermal drug delivery using microneedles
Bioanalysis and metabolite ID using LC-MS/MS
Drug development

Guangxi Zhai is a professor of pharmaceutics and director of department of pharmaceutics an also a research grant reviewer for National Natural Science Foundation and Shandong Provincial Natural Science Foundation, and has acquired more than 10 research grants and published more than 150 articles.

• Sustained-release, controlled-release and targeted drug delivery system
• Transdermal drug delivery system and nasal drug delivery system
• Biomedical materials and biological drugs drug delivery system
• Research on promoting the in vivo absorption of macromolecular drug and poorly water-soluble drug

Dr Run Zhang carried out his doctoral studies in the State Key Laboratory of Fine Chemicals at Dalian University of Technology, China. He moved to the Physics and Astronomy Department of Macquarie University as a postdoctoral research fellow immediately after finishing his PhD in July 2012. Then, he won a highly competitive Macquarie University Research Fellowship (MQRF), and took up this independent position in the Department of Chemistry and Biomolecular Science in January 2013. In January 2015, he was appointed as a visiting research fellow in Australian Institute of Bioengineering and Nanotechnology (AIBN), The University of Queensland (UQ). In December 2015, Dr Zhang was appointed as an adjunct associate professor in University of Science and Technology Liaoning, China. In February 2016, he re-located to AIBN, UQ to work on a research associate position. Dr Zhang is an expert in the field of synthetic and analytical chemistry, nanomaterial science, nano-/bio-interface (surface chemistry), and biophotonics. As an interdisciplinary scientist, he has made significant contributions in the respects of: i) development of a series of specific biosensors to probe important biomarkers in live systems; ii) fabricating functional nanomaterial for cancer early diagnosis and imaging guided tumour therapy; iii) inventing several chemosensors to detect the environmental pollutants; iv) engineering next generation nanotechnology for data security against forgery. Since 2014, Dr Zhang has voluntarily served as the editorial board and the reviewer for many international journals.

Functional bionanomaterials for imaging guided tumour therapy
Responsive biosensors for quantitative imaging of biomarkers in live systems
Organic/organometallic materials for photochemical and electrochemical application

Lorena Tavano graduated from the University of Calabria, Rende, Italy, with a degree in pharmaceutical chemistry and technology in 2006 and a Ph.D. degree in methodologies for the development of molecules of pharmacological interest from the same university in 2009. She moved to the Institute of Advanced Chemistry of Catalonia (CSIC, Barcelona, Spain) as a Researcher Fellow and in 2012 she came back to the University of Calabria as a Postdoc Researcher. Since 2006 she has been engaged in teaching activities as a Teaching Assistant and a Contract Professor. She is currently a Postdoctoral Fellow at the University of Calabria. 

Dr. Tavano focused her interest on the synthesis of surfactants and the on design of macromolecular systems in the form of vesicles (niosomes and liposomes), hydrogels, and liquid crystals for pharmaceutical, food, and cosmetic applications. She has a strong background in the field of controlled drug delivery.

Dr Shyamal Das is a Senior Lecturer in Pharmaceutical Science in the University of Otago (UOO). He obtained his PhD and pursued a Research Fellowship at Monash Institute of Pharmaceutical Sciences for five years when he developed a research track record in powders for inhalation. His unique experience in solid surface characterization to optimize respiratory delivery of powders is internationally recognized. The dearth of research in New Zealand on powders for inhalation stimulated him to initiate research on respiratory drug delivery. He has been successful in receiving grants and fellowships of over NZD1.25M as principal applicant including the prestigious nationally competitive grant from Health Research Council of New Zealand. Dr Das has published, mostly as a primary or senior author, 2 book chapters, 53 peer-reviewed articles and 60 other conference abstracts. Dr Das is the only external reviewer from Australasia for the Drug Delivery to the Lung Conference, the top conference in respiratory delivery annually held in Edinburgh. He is also on the editorial board of five international pharmaceutical journals, reviewers of top pharmaceutical journals, external examiners of PhD and Masters Theses examiners and a consultant to Pharmaceutical industries. This year Dr Das won Otago University’s Students Association’s top five teacher award for excellence in teaching.

Respiratory drug delivery
Powder formulations
Solid surface characterization
Powder generation

Zhirong Zhong is the School of Pharmacy Professor at Southwest Medical University. Dr. Zhong got her Ph.D. from West China School of Pharmacy, Sichuan University, China in 2010. She worked as visiting scholar in University of Nebraska Medical Center from 2015 to 2016. Dr. Zhong received the Sichuan Province Youth Science & Technology Progress Award. Her research interest focused on the novel drug-targeting delivery system.

Novel drug-targeting delivery system.

Rishabha malviya is working as an assistant professor in department of pharmacy at Galgotias University, India. He has finished Masters in pharmacy and pursuing PhD. He has got more than four years of research experience in pharma and published 118 articles combined in international and national journals and also overall 6+ years of experience in both industry and teaching together.

Development of novel drug delivery system, Drug targeting delivery

Xu Han is a cofounder and Chief Technology Officer at MD3 LLC, which is a mobile diagnosis detection device company, and C-Dots LLC which mainly focus on drug discovery. He obtained PhD degree from the University of Miami, FL, US. From 2008 to 2012, he achieved Bachelor of Science in chemistry from Nankai University, China, and Bachelor of Engineering from Nankai University and Tianjin University in chemical engineering from Tianjin University, China. He serves as the reviewer at Bioconjugate Chemistry, Journal of Colloid and Interface Science, Microchimica Acta, Colloids and Surfaces B: Biointerfaces, Future Science OA, BAOJ Chemistry, Recent Patents on Material Science, Journal of Parkinson’s Disease andAlzheimer's Disease, International Journal of Analytical Chemistry and other peer review journals. His research mainly focuses on Drug Delivery System, Biosensing Nanotechnology, Protein or Peptide Fibrillation, and Nanolithography.

His research mainly focuses on Drug Delivery System, Biosensing Nanotechnology, Protein or Peptide Fibrillation, and Nanolithography.

Dr. Alireza Heidari, Ph.D., D.Sc. is a Postdoctoral Research Fellow in Chemistry. He has got his Ph.D. and D.Sc. degrees form California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management and also in Nanochemistry and Molecular Structure Theory. His research interests are Biophysical Chemistry, Nanochemistry, Quantum Chemistry, Biomolecular and Vibrational Spectroscopy, Molecular Modeling and Structure, Theoretical, Computational and Mathematical Chemistry, Ab initio and Density Functional Methods. He has participated at more than one hundred reputed international conferences, seminars, congresses, symposiums and forums around the world as yet. Also, he possesses many published articles in Science Citation Index (SCI)/International Scientific Indexing (ISI) Journals. It should be noted that he has visited many universities or scientific and academic research institutes in different countries such as United States, United Kingdom, Canada, Australia, Netherlands, Belgium, Denmark, Greece, Russia, Estonia, Turkey, France, Swiss, Germany, Sweden, Italy, Spain, Portugal, Mexico, Japan, Malaysia, Thailand, Taiwan, South Korea, China, India, Qatar, United Arab Emirates, etc. as research fellow, sabbatical and volunteer researcher or visitor heretofore. He has a history of several years of teaching for college students and various disciplines and trends in different universities. Moreover, he has been a senior advisor in various industry and factories. He is expert in many computer programs and programming languages. Hitherto, he has authored more than ten books and book chapters in Chemistry. Syne, he has been awarded more than seven hundreds reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international journals, books and publishers. Hitherward, he is a member of more than two hundreds reputed international academic–scientific–research institutes around the world. It should be noted that he is currently the President of American International Standards Institute (AISI), Irvine, California, USA.

Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure.

Dr. Zongmin Zhao is currently a Postdoctoral Fellow at Harvard University in the John A. Paulson School of Engineering & Applied Sciences and Wyss Institute. He has received his Ph.D. degree from Virginia Polytechnic Institute and State University in 2017. Dr. Zhao has over 4 years of experience on developing nanoparticle-based platforms for biomedical applications, drug delivery, and vaccine development. Dr. Zhao has published many papers in highly reputed journals in the field of nanobiotechnology, nanomedicine, and drug delivery. He has delivered many oral and poster presentations in national and international conferences. He has also filed several patent disclosures and PCT patent applications. Dr. Zhao is a member of the American Chemical Society, the American Association for the Advancement of Science, and the American Institute of Chemical Engineers. In addition, Dr. Zhao are currently serving as reviewers for several peer-reviewed journals in the area of nanotechnology, nanomedicine, and drug delivery.

1) developing various nanoparticle platforms for biomedical applications, such as targeted drug delivery for disease treatment

2) studying the effect of properties of nanoparticles (such as shape and deformability) on their performances for specific purposes

3) developing next-generation nanoparticle-based nicotine vaccines for smoking cessation

4) developing efficient strategies for transdermal delivery of therapeutic drugs and vaccines.

I am currently working as an associate professor at Shri Anand College, Pathardi (MH), which is my native place. At Indian Institute of Technology with Dr. Jayandharan Rao I worked for post-doctoral experience where the area focus was Adeno associate viruses and nano particle hybrid gene delivery system for leukemia. At Centre for Nanotechnology and Advanced Biomaterials, SASTRA University, Thanjavur, India. Under the supervision of Prof. K. Uma Maheswari, Assistant Dean School of chemical and biotechnology I completed my Ph.D. and thesis titled was “Targeted liposomal si-RNA delivery against EpCAM expressing epithelial cancers” During my PhD I was JRF and SRF in the Department of Biotechnology and Indian Council for Medical Research, government of India funded project respectively. The major part of the thesis work have published in SCI index journal and have received adequate attention from scientific community.

Hybrid gene and drug System

Dr. Pirthi Pal Singh is an Associate Director in Formulation Research & Development at Dr. Reddy’s Laboratories Ltd, India. He earned his M Tech. & PhD in Bioprocess Technology from ICT, Mumbai, Diploma in Patent Law and Chemical Technology Management (Bronze Medalist) from University of Mumbai, India. Pirthi Pal Singh has over fifteen years of experience in pharmaceutical industries. He started his carrier in Sales & Marketing and Techno-Marketing and then moved to Drug Delivery Research. His major research interests include Nanotechnology based Drug Delivery Systems, Complex Generics Development, Melt Extrusion, Supercritical Fluid Processing, Taste-Masking, Mouth- Dissolving, Upstream and Downstream Processing of Biomolecules, Enzymatic Biotransformation and synthesis & formulation of inorganic compounds. He has worked on many NDA, NDA 505(b)(2) and ANDA projects and have a rich experience in technology transfer. He is an author/co-author for number of Research Publications, Presentations and Patents. He has published more than 17 International & National peer-reviewed research papers and has presented his research findings at more than 30 national and international conferences. He has filed about 10 patents, of which, 1 US and 4 Indian patents have been granted. He serves as a reviewer for a number of international peer reviewed journals. Pirthi Pal Singh has represented India as a Team Leader at the finals of Biotechnology - Young Entrepreneur Scheme at Oxford, UK, and Won Elevator’s Pitch Award. Recently, he was honored by Express Pharma (Indian Express Group) with Formulation Drug Development & Delivery (FDD) LEADERSHIP AWARD 2018 (Rising Star Category) for his contributions to Pharmaceutical Industry. He has won number of Best Poster Awards, Travel grants and received scholarship from Department of Biotechnology (DBT), Government of India. He was the Chairperson of Young Scientist Mentor-Protégé committee of Controlled Release Society, USA and is associated with CRS and AAPS on various volunteer activities.

Nanotechnology based Drug Delivery Systems, Novel Drug Delivery System in Injectable, Topical and Oral Complex ,Delivery systems like Liposomes, Microspehere, Solid Lipid Nanoparticles and Implants etc, Complex Generics Development, Techniques to enhance solubility, Polymorph stabilizations, Melt Extrusion, Supercritical Fluid Processing, Taste-Masking, Mouth- Dissolving etc., Upstream and Downstream Processing of Biomolecules, Enzymatic Biotransformation,  Synthesis inorganic compounds.

Dr. Venkatesan received B.Pharmacy degree in Pharmaceutical Science from Dr MGR Medical University, Tamil Nadu. He did his M.Tech in Biomedical Engineering from Jadavpur University, Kolkata, West Bengal. Then he joined Ph.D program in School of Medical Science and Technology of Indian Institute of Technology, Kharagpur as a full time institute research scholar. His areas of interests are Drug delivery, Pharmaceutics, Nanotechnology, Cancer Biology, Bone tissue engineering, Traumatic brain injury, Targeted drug delivery. He has published several papers in peer reviewed international journals, book chapters, invited talk and in international conference. He has been serving as editorial board member (in a journal), judge (conferences in USA), and reviewer in various journals.

As a researcher for the past 10 years after Phd, he has been involved with undergraduates both from USA and India. Since 2011 he has mentored several graduate and undergraduate students’ students at Health Science Center, Texas A&M University, College Station, TX, USA, University of Colorado Denver, USA and Oklahoma State University, USA, trained them in heat sensitive liposomes formulation and gemcitabine/paclitaxel loaded albumin nanoparticle by desolvation and microfluidizer, characterization, in vitro and in vivo mouse studies in athymic mouse tumor model (Prostate and colon). Currently he is working as a Research Scientist at New Jersey Institute of Technology.

Drug delivery, Pharmaceutics, Nanotechnology, Cancer Biology, Bone tissue engineering, Traumatic brain injury, Targeted drug delivery

Dr. Srinivas Ajjarapu, PhD, Formulation R&D Manufacturing Scientist, Thermo Fisher Scientific Pharmaceutical Development Services. He has gained International experience as a Researcher, he is been associated with many well-known research institutions like University of Mississippi, Oxford, Mississippi, Sun Pharmaceutical Industries Ltd. He is an active researcher and scientist with a strong desire to innovate pharmaceutical organisations. His research is primarily concerned with pharmaceutics and drug delivery. He is the author and co-author of numerous patents, book chapters, and scientific manuscripts on Pharmaceutics and Drug Delivery research for international peer-reviewed journals. Also from 2018 to 2019, he received the most prestigious awards.

• Recipient of AAiPS Research Award 2019 by American Association 2019 of Indian Pharmaceutical Scientists

• Poster was selected for Special Poster Collection at AAPS PharmSci360, 2019 San Antonio

• Initiated as an active member of Chi chapter at University of Mississippi in 2018 for 2018“Rho Chi Honor Society”

He is an expert in Pharmaceutics and Drug Delivery research, and his research has been recognised by international patents. He has made national and international contributions to science.

Pharmaceutics and Drug Delivery

Pharmaceutical professional with 8+ years’ industrial and academic research experience in product development and manufacturing operations. Proven track record in successfully developing and executing complex drug products with leadership, team building skills.

Oral Drug Delivery, Parenteral Drug Delivery, Biologics, Lipid Based Drug Delivery Systems

Ph.D. in Pharmaceutical Sciences with specialization in Industrial Pharmacy, Long Island University, Brooklyn, NY, USA.

Product development: Drug - Excipient compatibility Studies, Preformulation studies, Solubility enhancement studies, Tablet compaction simulation studies. • Technical skills: o Manufacturing Equipment: Tablet compression machine (Fette 1200 and 2090), Compaction Simulator (Presster), High Shear Granulator (Vector and Diosna), Tablet Coater (Compulab and Accela), Roller Compactor (Vector and Gerteis), Fluid Bed Dryer (FreundVector, GPCG-5 and Niro MP4), Solid State Size Reduction and Separation (Fitz mill and Comil), Encapsulator (MG2 Flexalab and H&K 1500) o Analytical Instruments: DSC (Q-2000), Dissolution Apparatus (Type I-II), PLM, XRD, FTIR, HPLC, UV Spectrophotometer, Zetasizer, Thermal Effusivity Sensor, • Quality test data analysis: Good Documentation skills in managing, gathering, and reporting test data using statistical methods like principal component analysis and partial least squares regression. • Computer skills: Proficient in Minitab 17, Unscrambler, Microsoft Office (MS Word, Excel, PowerPoint), Materials Studio, and WinNonlin. • Soft skills: Time management, Good communication, Conflict resolution, and Team management. • Mentoring Skills: Mentored technologists and junior level scientists to achieve their personal goals and organization goals.